Sg Americas Securities, LLC Glycomimetics Inc Transaction History

Sg Americas Securities, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$2.55 - $3.49 $47,952 - $65,629	18,805 New	18,805 $56,000
Q1 2021 May 13, 2021	SELL	$2.89 - $4.22 $42,378 - $61,882	-14,664 Closed	0 $0
Q4 2020 Feb 04, 2021	BUY	$2.69 - $4.24 $39,446 - $62,175	14,664 New	14,664 $55,000
Q3 2020 Nov 09, 2020	SELL	$3.07 - $5.0 $56,927 - $92,715	-18,543 Closed	0 $0
Q2 2020 Jul 20, 2020	BUY	$2.06 - $3.76 $11,882 - $21,687	5,768 Added 45.15%	18,543 $70,000
Q1 2020 Apr 30, 2020	BUY	$1.83 - $5.41 $23,378 - $69,112	12,775 New	12,775 $29,000
Q1 2018 May 03, 2018	SELL	$16.06 - $25.35 $98,865 - $156,054	-6,156 Closed	0 $0
Q4 2017 Jan 24, 2018	BUY	$10.51 - $17.22 $64,699 - $106,006	6,156	6,156 $103,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

Stay updated on Sg Americas Securities, LLC with notifications on news.